Rishita Chatterjee

This study develops a bispecific antibody targeting MERTK and EGFR to overcome drug resistance in lung cancer with mutations in exons 19, 20, and 21.

This study identifies a p53 mutation-specific immunotherapy strategy for ovarian cancer by targeting AREG and PD-L1, showing efficacy in mouse models and patient-derived organoids.

This study shows that TMPRSS2-ERG fusion promotes resistance to antiandrogens by interacting with GR, suggesting combined GR and AR inhibition could benefit tERG-positive prostate cancer patients.